ABL1 and acute lymphoblastic leukemia: These observations have reinforced the concept that BCR-ABL is the main target in CML and BCR-ABL+ ALL, but a combination of TKI and novel agents, affecting other cell pathways, might be more effective in preventing the outgrowth of resistant BCR-ABL+ cells and targeting the stem cell population.